Statement from President Stanley on the Accelerating Biomedical Research Act
At Stony Brook, groundbreaking biomedical research is advancing our understanding of disease and helping us discover new technology and medical treatments that lead to better outcomes. The National Institutes of Health (NIH) funding proposed in Senator Tom Harkin's (D-IA) Accelerating Biomedical Research Act will help continue this positive momentum and enable research universities to fulfill this important mission.
Funding to the NIH has remained flat in recent years, and uncertainty is growing over the ability of universities and other research institutions to conduct the noncommercial medical research underlying new preventative measures, diagnostic tools, treatments and cures. In response to significant concerns about the erosion of NIH’s purchasing power, Senator Harkin has introduced legislation, the Advancing Biomedical Research Act, which empowers Congress to provide up to 10 percent increases in NIH funding for FY 2015 and FY 2016, and up to 5 percent increases through 2021. These increases are more than justified by the scientific opportunity that was unleashed when the human genome was sequenced. And that’s just one of the developments that have set the stage for accelerated medical progress. We need to conquer Alzheimer’s disease, cancer, Parkinson’s disease, and other deadly and disabling health threats — and we can.
Samuel L. Stanley Jr., MD
President, Stony Brook University